Treating Together

In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.

Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.

In this episode of Targeted Talks, Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial (NCT05032820) of idecabtagene vicleucel (ide-cel; Abecma), a study focused on patients with multiple myeloma who had a suboptimal response to first-line therapy, including autologous hematopoietic cell transplant and lenalidomide (Revlimid) maintenance.

David A. Russler-Germain, MD, PhD, physician-scientist at Washington University School of Medicine and Siteman Cancer Center, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan (https://www.targetedonc.com/view/fda-approves-dato-dxd-in-hr-her2-breast-cancer) for the treatment of patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior systemic therapy.

In this episode of Targeted Talks, Sanjay K. Juneja, MD, hematologist & medical oncologist at Mary Bird Perkins Cancer Center, discusses the exciting advancements of artificial intelligence in 2024, specifically focusing on its transformative impact on early cancer detection.

In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, executive medical director of oncology services at St. Elizabeth Healthcare, discusses the transformative impact of artificial intelligence in oncology.

In this episode of Targeted Talks, Seth Wander, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor at Harvard Medical School, discusses the clinical importance of ESR1 mutations in hormone receptor-positive metastatic breast cancer and how these mutations influence treatment approaches.

Antonious Hazim, MD, hematology medical oncology fellow at Mayo Clinic, Rochester, Minnesota, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.

In this episode of Targeted Talks, Virginia Kaklamani, MD, DSc, professor of medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center San Antonio and the leader of the breast cancer program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discusses the background, findings, and implications of the phase 3 EMERALD...

In this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm.

In this episode of Emerging Experts, Paolo Tarantino, MD, researcher at the European Institute of Oncology, and clinical research fellow at Dana-Farber Cancer Institute, discusses the latest developments in breast cancer research and treatment, focusing on the evolving understanding of HER2-low breast cancer subtypes and the potential advantages of using antibody-drug conjugates.

In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.

In this episode of Emerging Experts, Yu Fujiwara, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

In this episode of Targeted Talks, Nini Wu, MD, MBA, chief medical and development officer at Cardinal Health, shares her insights on the ever-changing world of technology in the community oncology setting.

In the latest episode of Emerging Experts, Michael LaPelusa, MD, hematology and oncology fellow at MD Anderson Cancer Center, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, director of breast surgery, Robert Wood Johnson (RWJ), Barnabas Health, director of women’s oncologic health, RWJ Barnabas Health and Rutgers Cancer Institute, and head of breast surgery, Cooperman Barnabas Medical Center, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testi...

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

In season 5, episode 3 of Targeted Talks, Ben Derman, MD, assistant professor of medicine at the University of Chicago Medical Center, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, assistant professor of medicine at NYU Langone Perlmutter Cancer Center, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, president of the Allina Health Cancer Institute and the chief academic officer for Allina Health, delves into the critical topic of prostate cancer screening, particularly for men within a community setting, and discusses some of the recent advancements in the prostate cancer space.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab c in advanced or metastatic non–small cell lung cancer.

In our third episode of Emerging Experts, host Jordyn Sava is joined by Matthew Hadfield, DO, a third-year hematology/oncology fellow at Brown University, to discuss his interest and research in immunotherapy toxicities.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with with metastatic colorectal cancer.

In this episode of Emerging Experts, host Jordyn Sava is joined by Hemali Batra-Sharma, MD, fellow, Hematology/Oncology, University of California San Diego (UCSD) Medical Center, UCSD Health, to discuss insights into her passion for oncology and some of the experiences that have helped to shape her career.

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD, hepatobiliary and pancreas surgeon at the Mayo Clinic in Rochester, Minnesota, discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

In our first episode of Emerging Experts, Aakash Desai, MD, MPH, discusses his journey through the oncology field by reminiscing on the encouraging guidance of his mentors, personal research goals, and his experiences thus far as an oncologist.

Alicia Morgan, MD, MPH on real-world data from the DEAR study.

An interview with Benny Weskler, MBA, MD, FACS, FACCP of Allegheny Health Network.

Federico Albrecht, MD discusses 2 small cell lung cancer cases.

Craig Horbinski, MD, PhD, unpacks the NCCN Clinical Practice Guidelines for central nervous system tumors.

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD of Massachusetts General Hospital discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

An interview with Ruchi Garg, MD of City of Hope.

An interview with Warren Swegal, MD.

An interview with Alice P. Chen, MD of the National Cancer Institute.

Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the present and future of prostate cancer precision medicine.

A talk with Sara A. Hurvitz, MD about advances in the HER2-positive breast cancer space.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, of Dana-Farber Cancer Institute discuses new studies in gastrointestinal malignancies.

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD of Cancer Treatment Centers of America, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD of Cancer Treatment Centers of America Atlanta, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

In season 3, episode 9 of Targeted Talks, Mohammed Salhab, MD, Chris Fine, MD, FACC, cardiologist at National Jewish Health, have a special discussion about cardiotoxicity from immune checkpoint inhibitor therapy in patients with cancer.

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.